These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29728700)

  • 21. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.
    Bhutani M; Foureau DM; Robinson M; Guo F; Fesenkova K; Atrash S; Paul B; Varga C; Friend R; Pineda-Roman M; Rigby K; Symanowski JT; Norek S; Tucker MR; Druhan LJ; Voorhees PM; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):535-544.e1. PubMed ID: 37127471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
    Derman BA; Cooperrider J; Rosenblatt J; Avigan DE; Rampurwala M; Barnidge D; Major A; Karrison T; Jiang K; Ramsland A; Kubicki T; Jakubowiak AJ
    Blood Cancer J; 2024 May; 14(1):87. PubMed ID: 38811560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
    Leypoldt LB; Tichy D; Besemer B; Hänel M; Raab MS; Mann C; Munder M; Reinhardt HC; Nogai A; Görner M; Ko YD; de Wit M; Salwender H; Scheid C; Graeven U; Peceny R; Staib P; Dieing A; Einsele H; Jauch A; Hundemer M; Zago M; Požek E; Benner A; Bokemeyer C; Goldschmidt H; Weisel KC
    J Clin Oncol; 2024 Jan; 42(1):26-37. PubMed ID: 37753960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
    Kazandjian D; Hill E; Dew A; Morrison C; Roswarski J; Korde N; Emanuel M; Petrosyan A; Bhutani M; Calvo KR; Dulau-Florea A; Kwok M; Lee MJ; Lee S; Lindenberg L; Mailankody S; Manasanch E; Maric I; Mena E; Patel N; Tageja N; Trepel JB; Turkbey B; Wang HW; Wang W; Yuan C; Zhang Y; Braylan R; Choyke P; Stetler-Stevenson M; Steinberg SM; Figg WD; Roschewski M; Landgren O
    JAMA Oncol; 2021 Nov; 7(11):1678-1685. PubMed ID: 34529025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
    Stewart AK; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Buchanan J; Cocks K; Yang X; Xing B; Zojwalla N; Tonda M; Moreau P; Palumbo A
    J Clin Oncol; 2016 Nov; 34(32):3921-3930. PubMed ID: 27601539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.
    Campioni M; Agirrezabal I; Hajek R; Minarik J; Pour L; Spicka I; Gonzalez-McQuire S; Jandova P; Maisnar V
    Eur J Health Econ; 2020 Mar; 21(2):219-233. PubMed ID: 31673898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
    Lee JH; Park Y; Kang KW; Lee JJ; Lee HS; Eom HS; Do YR; Kim JS; Yoon SS; Shin DY; Koh Y; Kim KH; Lee WS; Jo JC; Lee YJ; Lee JY; Kim DS; Shim H; Chang MH; Kim SH; Min CK;
    Ann Hematol; 2021 Aug; 100(8):2051-2059. PubMed ID: 33447888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
    Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
    J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
    Tan CR; Derkach A; Nemirovsky D; Ciardiello A; Diamond B; Hultcrantz M; Hassoun H; Mailankody S; Shah U; Maclachlan K; Patel D; Lahoud OB; Landau HJ; Chung DJ; Shah GL; Scordo M; Giralt SA; Lesokhin A; Usmani SZ; Landgren O; Korde N
    Blood Cancer J; 2023 Jul; 13(1):112. PubMed ID: 37491332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
    Leypoldt LB; Besemer B; Asemissen AM; Hänel M; Blau IW; Görner M; Ko YD; Reinhardt HC; Staib P; Mann C; Lutz R; Munder M; Graeven U; Peceny R; Salwender H; Jauch A; Zago M; Benner A; Tichy D; Bokemeyer C; Goldschmidt H; Weisel KC
    Leukemia; 2022 Mar; 36(3):885-888. PubMed ID: 34732857
    [No Abstract]   [Full Text] [Related]  

  • 32. [Carfilzomib, lenalidomide, and dexamethasone therapy for refractory and relapsed multiple myeloma: a single-center study of 29 patients].
    Okazuka K; Ishida T; Sato K; Miyazaki K; Yoshiki Y; Abe Y; Tsukada N; Suzuki K
    Rinsho Ketsueki; 2018; 59(6):698-700. PubMed ID: 29973446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status.
    Landgren O
    Semin Oncol; 2016 Dec; 43(6):703-706. PubMed ID: 28061991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
    Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
    Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
    Suzuki K; Ri M; Chou T; Sugiura I; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Ota K; Iida S
    Cancer Sci; 2017 Mar; 108(3):461-468. PubMed ID: 28092421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
    Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
    Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies.
    Landgren O; Kazandjian D; Roussel M; Jasielec J; Dytfeld D; Anderson A; Kervin TA; Iskander K; McFadden I; Jakubowiak AJ
    Leuk Lymphoma; 2022 Oct; 63(10):2413-2421. PubMed ID: 35549810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
    Alsina M; Landgren O; Raje N; Niesvizky R; Bensinger WI; Berdeja JG; Kovacsovics T; Vesole DH; Fang B; Kimball AS; Siegel DS
    Am J Hematol; 2021 Feb; 96(2):226-233. PubMed ID: 33125764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
    Piedra K; Peterson T; Tan C; Orozco J; Hultcrantz M; Hassoun H; Mailankody S; Lesokhin A; Shah U; Lu S; Patel D; Derkach A; Wilkins CR; Korde N
    Br J Haematol; 2022 Jan; 196(1):105-109. PubMed ID: 34396516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.